Scientists at Baylor College of Medicine have developed DeepMVP, an artificial intelligence model that predicts sites of post-translational modifications (PTMs) in proteins and how genetic variants may alter these modifications, impacting protein function and disease. The model was trained using PTMAtlas, a comprehensive database of nearly 400,000 experimentally verified PTM sites from public datasets. Understanding PTM alterations can guide therapeutic development for diseases where aberrant protein modifications play a role, such as cancer and neurological disorders.